Dicot Pharma to present at Oppenheimer Life Sciences Company Showcase
Dicot Pharma has been invited to participate in the Oppenheimer Life Sciences Company Showcase taking place today. In a recent report published by the US investment bank Oppenheimer, longevity is identified as the next major growth area for biotech investments. The report highlights the strong link between erectile dysfunction (ED) and longevity and identifies Dicot Pharma's candidate for the treatment of ED, LIB-01, as particularly interesting.
Longevity, or healthy aging, can be described as living a long life in good health. Research and innovation in the longevity field are considered among the most exciting and fast-growing areas for life science investments. Oppenheimer recently released a report pointing to the life-extending benefits of treating ED and its potential role as a marker for underlying diseases. The report also highlights the shortcomings of current ED treatments and emphasizes the need for new modalities. Dicot Pharma's candidate LIB-01 is singled out as particularly promising due to its long duration of action and competitive safety profile observed to date in clinical development, as well as its differentiated mechanism of action. Unlike current ED treatments on the market, LIB-01 is not a PDE5-inhibitor, and has the potential to be first-in-class in ED treatment.
Dicot Pharma has been invited to Oppenheimer's company showcase, where life science companies representing the next wave of innovation in the field will present their work.
"The fact that erectile dysfunction is recognized as a key factor within longevity, and that our ED drug candidate LIB-01 is being specifically highlighted, is a significant confirmation of the relevance of our work. We look forward to sharing further insights during today's event," says Elin Trampe, CEO of Dicot Pharma.
For further information, please contact:
Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: [email protected]
About Dicot Pharma AB
Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma's business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market.
Dicot Pharma is listed on Nasdaq First North and has approximately 15,300 shareholders. FNCA Sweden AB is appointed Certified Adviser. For more information, please visit www.dicotpharma.com.
This is a translation from the Swedish original. In case of differences between versions, the Swedish version prevails.
Om Dicot Pharma
Dicot utvecklar ett modernt potensläkemedel som ska behandla erektionssvikt och för tidig utlösning bättre än befintliga preparat.
Handelsinformation
IR-Kontakt
